Phase II trial of trastuzumab in combination with cytotoxic chemotherapy for treatment of metastatic osteosarcoma with human epidermal growth factor receptor 2 overexpression: a report from the children's oncology group
about
Emerging concepts for PI3K/mTOR inhibition as a potential treatment for osteosarcomaTargeted immunotherapy for pediatric solid tumorsPresent Advances and Future Perspectives of Molecular Targeted Therapy for OsteosarcomaChimeric Antigen Receptor-Modified T Cells for Solid Tumors: Challenges and ProspectsImmunotherapy of Childhood SarcomasSpinal osteosarcomaCellular immunotherapy for pediatric solid tumorsChildren's Oncology Group's 2013 blueprint for research: bone tumorsReceptor tyrosine kinases: Characterisation, mechanism of action and therapeutic interests for bone cancersA summary of the osteosarcoma banking efforts: a report from the Children's Oncology Group and the QuadW FoundationEvaluation of CD146 as Target for Radioimmunotherapy against OsteosarcomaOsteosarcoma Overview.Cardiovascular disease in adult survivors of childhood cancer.Epidemiology and therapies for metastatic sarcomaHER-2 expression is not prognostic in osteosarcoma; a Children's Oncology Group prospective biology study.Managing chemotherapy-related cardiotoxicity in survivors of childhood cancers.Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive SarcomaNeoadjuvant chemotherapy (NCT) plus targeted agents versus NCT alone in colorectal liver metastases patients: A systematic review and meta-analysisA novel ATG4B antagonist inhibits autophagy and has a negative impact on osteosarcoma tumors.Bone Sarcomas in Pediatrics: Progress in Our Understanding of Tumor Biology and Implications for Therapy.HER-2 expression in biopsy and surgical specimen on prognosis of osteosarcoma: A systematic review and meta-analysis of 16 studies.Predictive properties of DNA methylation patterns in primary tumor samples for osteosarcoma relapse status.Molecular profiling of childhood cancer: Biomarkers and novel therapiesCellular and Antibody Based Approaches for Pediatric Cancer Immunotherapy.Identification of Synergistic, Clinically Achievable, Combination Therapies for OsteosarcomaThe Current and Future Therapies for Human Osteosarcoma.Impaired mitochondrial function is abrogated by dexrazoxane in doxorubicin-treated childhood acute lymphoblastic leukemia survivors.Immunotherapy in pediatric malignancies: current status and future perspectivesA review of targeted therapies evaluated by the pediatric preclinical testing program for osteosarcoma.Impact of hemochromatosis gene mutations on cardiac status in doxorubicin-treated survivors of childhood high-risk leukemiaIsocitrate dehydrogenase 2 mutation is a frequent event in osteosarcoma detected by a multi-specific monoclonal antibody MsMab-1.Molecular mechanisms of chemoresistance in osteosarcoma (Review).Targeted therapy for soft tissue sarcomas in adolescents and young adults.The adolescent and young adult with cancer: state of the art -- bone tumors.Chemotherapy for osteosarcoma - where does it come from? What is it? Where is it going?Treatment-related cardiotoxicity in survivors of childhood cancer.Current therapeutic strategies and novel approaches in osteosarcoma.Advances in therapy for pediatric sarcomas.ErbB receptors as prognostic and therapeutic drug targets in bone and soft tissue sarcomas.The Potential of panHER Inhibition in Cancer.
P2860
Q26738598-9BD81532-D6A9-45F6-A6BE-1629A2D7BEE7Q26747703-888E9E2A-601F-4B40-B0FC-7F21A37CE932Q26750631-C53A947F-887E-4ECC-AF94-282DF90BA462Q26753082-C13D2625-E9FD-4330-8CC3-F7B3E476D9A5Q26795369-6369C2C3-0578-4FF5-83FE-BF97BCD0CD17Q26996533-F26C2BE1-6DB6-4D41-8B78-5E0E7039E203Q27014912-74162695-BB00-49D3-A705-E399A95DCC23Q27027664-DDB460D3-2DB1-47A5-9050-7BFBD24C0D19Q28082793-209DAA86-31DD-46D8-B2D8-11A70122B741Q28386370-066BFFF2-A261-4639-9B35-7567645AB054Q28552916-E0FEE384-686A-4C1C-80B9-9D11B6677004Q33725511-18F18E8D-CEA0-4543-B7A9-F8F6C6548BF9Q34042984-33B2F97F-A207-44EB-B462-F24CE0B0F734Q34652142-B3C05486-D389-4BE9-8AC1-3ED162495EEEQ34887225-181179E6-5393-4435-9FCE-E3D4C16B5408Q35562745-15B1B3C6-93B8-476D-B2B9-02598EAAD812Q35598804-52776D49-148C-4936-ADC6-9FF92CD9C226Q35826810-9455CE08-5EDF-40A7-B6B9-84A16AFB2017Q35852826-3D9372C0-5896-4A72-9145-F8094C87E969Q35894540-291CC33B-FDEA-474C-819B-8CA41DF3A155Q36046928-C2DB72C8-A3EC-4E65-84C4-A18D80E041C6Q36211310-44CC101A-6D46-46EC-8553-138107B23296Q36250783-78CB6B5F-123E-4A28-A71F-ABBF928991AFQ36261159-0A49CA59-C435-40AD-9A6A-9829F8361BBFQ36316518-E8D9049F-DE11-45E8-B1A9-00360F7C8925Q36514299-2A89393F-2271-4043-A4F1-57A5E934CA9FQ36649653-6538F47D-DE81-4990-9167-58EBD90747FDQ36691818-9B99A4D2-1580-414D-A1BA-AEC087628934Q36888962-05BF2E5C-94E0-464B-BAFA-E870F17DFD5AQ37209968-AD06DBBA-023C-4F58-A025-408CBA5D38F1Q37481150-01C893F4-CF77-4015-9CCE-25C5580ACFBBQ37719938-B88552B7-C0AB-4C73-B440-4565D3746F1AQ37742014-F4257A79-59B2-4B06-93D2-26B0587055F7Q38108248-F4D6DABC-9203-4697-8894-9C43493E8487Q38126943-A009AB3E-2DAC-4081-BDC0-5C6CF45C876AQ38156036-D3D45FCF-8C13-439E-996C-0036D548CAFCQ38161735-CF80E87F-56A2-4F75-80DD-F1FFCD3E3E83Q38217354-B393396A-C03B-46E4-9029-3A905DAB2056Q38263000-6D317E2C-90CB-437D-A4D5-67C92BCDBB8EQ38352587-F9E03C8A-B098-45E4-9D36-3D43A075C028
P2860
Phase II trial of trastuzumab in combination with cytotoxic chemotherapy for treatment of metastatic osteosarcoma with human epidermal growth factor receptor 2 overexpression: a report from the children's oncology group
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Phase II trial of trastuzumab ...... the children's oncology group
@ast
Phase II trial of trastuzumab ...... the children's oncology group
@en
type
label
Phase II trial of trastuzumab ...... the children's oncology group
@ast
Phase II trial of trastuzumab ...... the children's oncology group
@en
prefLabel
Phase II trial of trastuzumab ...... the children's oncology group
@ast
Phase II trial of trastuzumab ...... the children's oncology group
@en
P2093
P2860
P921
P356
P1476
Phase II trial of trastuzumab ...... the children's oncology group
@en
P2093
Allen Goorin
Donald A Barkauskas
Gene P Siegal
George Douglas Letson
Holcombe Grier
Karen Marcus
Mark Bernstein
Mark Krailo
Meenakshi Devidas
P2860
P304
P356
10.1200/JCO.2011.37.4546
P407
P577
2012-06-04T00:00:00Z